MuScreen™

Screen your compound across well validated panels of Syngeneic and Tumor Homograft models to accelerate your drug development

High Throughput In Vivo Screens for Evaluating Immunotherapies

The MuScreen platform is the only high throughput in vivo screen to evaluate immune modulating agents across preselected panels of well-characterized syngeneic and tumor homograft (MuPrime™) models.

This screen provides a cost effective and time efficient way to fast-track in vivo preclinical immunotherapy development.

Choose MuScreen to:

  • Quickly identify responder models or markers saving time and improving efficiency
  • Evaluate the efficacy of your compound across well-characterized syngeneic and tumor homograft models
  • Investigate pharmacodynamic (PD) effects using our syngeneic model panels
  • Benefit from Crown Bioscience covering the cost of the vehicle group for all models
  • Benefit from a discount on shared control groups

Select the Models and Study Design To Suit Your Program

Model Type Model  Features Efficacy PD
US China US China
Syngeneic Display immune heterogeneity and diversity
observed in the clinic
6
models
12
models
6
models
12
models
Tumor Homograft Transplants of GEMM tumors into a syngeneic host,
preserving original GEMM tumor molecular and
histopathology and clinically relevant oncogenic
driver mutations
  6
models
   

MuScreen Schedules

 

12 Model Syngeneic Efficacy and PD Mode

Study Site: Crown Bioscience China

Registration Deadline Study Initiation
January 17th, 2023 February 24th, 2023
April 14th, 2023 May 12th, 2023
July 14th, 2023 August 11th, 2023
September 15th, 2023 October 13th, 2023

6 Model Syngeneic Efficacy and PD Mode

Study Site: Crown Bioscience San Diego

Registration Deadline Study Initiation
January 13th, 2023 February 13th, 2023
March 17th, 2023 April 17th, 2023
May 19th, 2023 June 19th, 2023
August 11th, 2023 September 11th, 2023

6 Model Tumor Homograft Efficacy Mode

Study Site: Crown Bioscience China

Registration Deadline Study Initiation
January 13th, 2023 February 24th, 2023
May 9th, 2023 June 16th, 2023
September 1st, 2023 October 13th, 2023

Syngeneic Model Panel

 

Choose between 6 or 12 well-characterized syngeneic models to evaluate your I/O compound efficacy or PD effect.

Cancer Type Model Mouse Strain Immune Cell Profiling RNAseq Baseline Proteomics Data
Breast EMT6* BALB/c Yes Yes Yes
Colorectal CT26.WT* BALB/c Yes Yes Yes
  MC38 C57BL/6 Yes Yes Yes
Kidney Renca BALB/c Yes Yes Yes
Liver H22^ BALB/c Yes Yes Yes
  Hepa 1-6 C57BL/6 Yes Yes Yes
Lung LL/2 C57BL/6 Yes Yes Yes
Lymphoma A20* BALB/c Yes Yes Yes
Melanoma B16-BL6 C57BL/6 Yes Yes Yes
  B16-F10* C57BL/6 Yes Yes Yes
Pancreatic Pan02* C57BL/6 Yes Yes Yes
Prostate RM-1* C57BL/6 Yes Yes Yes

* Models are run at our US site in a 6 model MuScreen
^ This line is not applicable for FACS

Syngeneic models display immune heterogeneity and diversity observed in the clinic, enabling comprehensive evaluation of efficacy and PD effects of your immune modulating agents.

Key advantages of syngeneic models include:

  • Fully immune competent
  • Rapid model establishment
  • Availability of historical data

Our syngeneic models are highly characterized, with data including:

  • Immune checkpoint inhibitor benchmarking
  • Baseline tumor immune profile
  • Tumor RNAseq

Visit MuBase® for all available model data

Learn More

Tumor Homograft Model Panel

 

Test your I/O agent antitumor efficacy in vivo on a panel of our unique tumor homograft models

Cancer Type Model Mutations/Carcinogen Strain
Background
Immune
Profiling
RNAseq Growth
Curve
SoC Data
Breast mBR6004 MMTV-PyVT TG FVB/N Yes Yes Yes Yes
Liver mLI9040 Alb-Cre; CAG-LSL-cMyc C57BL/6 Ongoing Yes Yes Yes
Lung mLU6045 Kras(G12D); P53-/- C57BL/6 Yes Yes Yes Yes
Pancreatic mPA6115 Kras(G12D); P53-/-; PDx-1 cre C57BL/6 Yes Yes Yes Yes
Sarcoma mSA9003 P53-/- C57BL/6 Yes Yes Yes Yes
Skin mSK6005 ApcMin/+ C57BL/6 Yes Yes Yes Yes

Tumor homografts are transplants of spontaneous or carcinogen-induced GEMM tumors in immunocompetent syngeneic hosts. They preserve the original GEMM tumor molecular and histopathology as well as clinically relevant oncogenic driver mutations.

Our MuPrime tumor homografts have been developed to broaden the number and molecular pathology of preclinical syngeneic models for in vivo pharmacology studies.

Key advantages of MuPrime tumor homografts include:

  • Fully immune competent
  • Relevant tumor stroma
  • Mimic original GEMM tumor molecular and histopathology
  • Encompass disease-specific mutations of human cancers
  • Similar disease progression as original GEMM tumors

Our tumor homograft models are well characterized with available characterization data including:

  • Immune checkpoint inhibitor benchmarking
  • Baseline tumor immune profile
  • Tumor RNAseq

Visit MuBase for all available model data

Learn More

Efficacy and PD Mode

 

MuScreen Efficacy and PD Mode are run following a preset schedule along with a shared vehicle group.

The main study endpoint for the efficacy mode is Tumor Growth Inhibition (TGI) with optional terminal Mouse I/O RNA-Seq Panel readout, FACS and IHC.

In the PD mode, choose between FACS analysis of tumor infiltrating lymphocytes and tumor associated macrophages at selected time points, and Mouse I/O RNA-Seq Panel which comprehensively profiles 1080 genes associated with tumor immunity, as your main endpoint. Additional endpoints include cytokine panel profiling in blood and tumor, IHC for biomarker analysis on tumor tissues, blood cells, lymph nodes, and spleen cells.

Frozen or fixed tumors are available on request for both modes.

Access MuBase® Database

 

Find the best models for the preclinical evaluation of your immuno-oncology agent by logging on to Crown Bioscience’s searchable database of well-characterized and validated mouse models. Crown Bioscience offers a wide selection of murine research models including syngeneic, tumor homograft (MuPrime), GEMM, and humanized drug target (HuGEMM) models to screen your compounds of interest.

Access MuBase to explore genomic, molecular, and phenotypic data including tumor growth curves, standard of care response, histopathology data, and immune cell profiling data on this wide collection of immuno-oncology mouse models.

Browse, search, and stratify across different model types

MuPrime Database

Review treatment data for specific models including immune checkpoint inhibitors

MuPrime Soc Graph

Register Now



Request MuScreen Pricing

Interested in enrolling your Immuno-Oncology Agents? or have more questions?